



**BILAG 8.1.E TIL VEDTÆGTER FOR
ZEALAND PHARMA A/S**

**EXHIBIT 8.1.E TO THE ARTICLES OF
ASSOCIATION FOR
ZEALAND PHARMA A/S**



INDHOLDSFORTEGNELSE/TABLE OF CONTENTS

1	FORMÅL.....	3
1	PURPOSE	3
2	TILDELING AF WARRANTS.....	3
2	GRANT OF WARRANTS.....	3
3	ALMINDELIG UDNYTTELSE AF WARRANTS	4
3	ORDINARY EXERCISE OF THE WARRANTS	4
4	EKSTRAORDINÆR UDNYTTELSE AF WARRANTS	5
4	EXTRAORDINARY EXERCISE OF THE WARRANTS.....	5
5	PRAKTISK UDNYTTELSE AF WARRANTS.....	5
5	PRACTICALITIES IN CONNECTION WITH EXERCISE OF THE WARRANTS	5
6	TEGNINGSKURS FOR AKTIER VED UDNYTTELSE AF WARRANTS	5
6	SUBSCRIPTION PRICE FOR SHARES IN CONNECTION WITH THE EXERCISE OF WARRANTS	5
7	REGULERING AF VILKÅR FOR WARRANTS VED VISSE DEFINEREDE ÆNDRINGER I SELSKABETS KAPITALFORHOLD	6
7	ADJUSTMENT OF THE CONDITIONS FOR WARRANTS IN CASE OF CERTAIN DEFINED CHANGES IN THE COMPANY'S CAPITAL STRUCTURE.....	6
8	OMSÆTTELIGHED.....	6
8	TRANSFERABILITY	6
9	VILKÅR FOR NYE AKTIER UDSTEDT VED UDNYTTELSE AF WARRANTS	6
9	CONDITIONS FOR NEW SHARES ISSUED FOLLOWING EXERCISE OF THE WARRANTS	6
10	KAPITALFORHØJELSE VED UDNYTTELSE AF WARRANTS	6
10	CAPITAL INCREASE IN CONNECTION WITH THE EXERCISE OF THE WARRANTS	6
11	OMKOSTNINGER I FORBINDELSE MED UDSTEDELSE AF AKTIER	7
11	COSTS RELATED TO THE ISSUE OF SHARES	7
12	OPHØR AF ANSÆTTELSESFORHOLDET - WARRANTINDEHAVERE, DER ER MEDARBEJDERE	7
12	CEASE OF EMPLOYMENT STATUS - WARRANT HOLDERS WHO ARE EMPLOYEES.....	7
13	INSIDERHANDEL	7
13	INSIDER TRADING.....	7
14	SKATTEMÆSSIGE FORHOLD	7
14	TAX IMPLICATIONS.....	7
15	SPROG	7
15	LANGUAGE.....	7



1 Formål

- 1.1 På bestyrelsesmødet i Zealand Pharma A/S ("Selskabet") den 8. februar 2013 blev der i overensstemmelse med vedtægternes punkt 8.1 vedtaget følgende nye bestemmelser vedrørende udstedelse af warrants til visse af Selskabets medarbejdere ("Warrantinnehaver") ("Warrants").

1.2 Bestyrelsen har besluttet at udstede op til 389.762 warrants i Selskabet til tegning af op til 389.762 aktier til kr. 1,00 (nominelt kr. 389.762) i henhold til vedtægternes punkt 8.1. Det konkrete antal warrants tildelt udgør 386.012.

- 1.3 Tegning af Warrants har fundet sted ved elektronisk underskrivelse af warrantaftaler ("Warrantagreementer").

- 1.4 Warrants berettiger Warrantinnehaveren til at tegne aktier på de i bilag 8.1.A som modificeret ved bilag 8.1.C til Selskabets vedtægter anførte vilkår, således gælder endvidere følgende modifikationer til bilag 8.1.A som modificeret ved bilag 8.1.C:

2 Tildeling af Warrants

- 2.1 Hver Warrantinnehaver har fået tildelt det antal warrants i Selskabet, som er anført i Selskabets meddelelse til Warrantinnehaveren i "Aktionærportalen" på Selskabets hjemmeside, som vil være

1 Purpose

At the board meeting held in Zealand Pharma A/S (the "Company") on 8 February 2013, the following new provisions were adopted in accordance with Article 8.1 of the Articles of Association concerning the issuing of warrants to certain employees of the Company (the "Warrant Holder") ("Warrants").

The Board of Directors has decided to issue up to 389,762 Warrants in the Company for the subscription of up to 389,762 shares of DKK 1.00 (nominally DKK 389,762) according to Article 8.1 of the Articles of Association. The final number of warrants granted is 386,012.

The subscription of Warrants took place by electronically signing of warrant agreements (the "Warrant Agreements")

The Warrants entitle the Warrant Holder to subscribe for shares on the terms and conditions stipulated in exhibit 8.1.A, as amended by exhibit 8.1.C of the Articles of Association of the Company. Furthermore, the following amendments to exhibit 8.1.A, as amended by exhibit 8.1.C shall apply:

2 Grant of Warrants

Each Warrant Holder has been granted such number of warrants in the Company as set out in the message from the Company to the Warrant Holder made available at "Aktionærportalen" at the website of the Com-



tilgængelig den 11. februar 2013 ("Warrants") i overensstemmelse med vilkårene i Aftalen og Selskabets vedtægter.

- 2.2 Tildeling af Warrants sker uden beregning.
- 2.3 Hver Warrant berettiger Warrantinnehaveren til at tegne 1 aktie à nominelt kr. 1,00 i Selskabet i henhold til de relevante bestemmelser anført i punkt - 5 til den i punkt 6 fastsatte tegningskurs.
- 2.4 I forbindelse med Selskabets aktiebog skal der føres en fortægnelse over samtlige udstedte Warrants.

3 Almindelig udnyttelse af Warrants

- 3.1 Warrants kan udnyttes i perioden fra 10. februar 2016 til og med 10. februar 2018 ("Udnyttelsesperioden") inden for de udnyttelsesvinduer anført i punkt 3.2. Warrants, der ikke er blevet udnyttet på eller inden den sidste dag i Udnyttelsesperioden, bortfalder automatisk og bliver ugyldige uden yderligere varsel og/eller kompenstation til Warrantinnehaveren.
- 3.2 Inden for Udnyttelsesperioden kan Warrants udnyttes fire gange om året i et 4 ugers udnyttelses-vindue, der begynder på tidspunktet for offentliggørelse af enten Selskabets årsregnskab eller perioderegnskab (henholdsvis 3, 6 eller 9 måneder).

pany on 11 February 2013 (the "Warrants") in accordance with the terms set forth in this Agreement and the Company's Articles of Association.

The Warrants are granted free of charge.

Each Warrant entitles the Warrant Holder to subscribe for 1 share of nominal value DKK 1.00 in the Company pursuant to the relevant conditions as set forth in Clauses 3 - 5 and at the relevant subscription price as determined in Clause 6.

In connection with the Company's register of shareholders, a register of all issued Warrants shall be kept.

3 Ordinary Exercise of the Warrants

The Warrants may be exercised in the period from 10 February 2016 until (and including) 10 February 2018 ("Exercise Period") within the windows set forth in Clause 3.2. Warrants which have not been exercised on or before the last day of the Exercise Period will automatically lapse and become void without any further notice and/or compensation to the Warrant Holder.

Within the Exercise Period, the Warrants may be exercised four times a year during a 4-week window starting from the time of publication of either the Company's annual report or quarterly or semi-annual reports (respectively 3, 6 and 9 months).



3.3 Warrantinnehaveren er berettiget til at udnytte alle eller en del af sine Warrants. Warrantinnehaveren kan dog ikke udnytte mindre end 25 procent ad gan-gen af det samlede antal Warrants, der er blevet tildelt Warrantinnehaveren i henhold til Aftalen.

4 Ekstraordinær udnyttelse af Warrants

4.1 Se bilag 8.1.A (ingen ændringer).

5 Praktisk udnyttelse af Warrants

5.1 Se bilag 8.1.C (ingen ændringer).

6 Tegningskurs for aktier ved udnyttelse af Warrants

6.1 Hver Warrant giver Warrantinnehaveren ret til at tegne 1 aktie à nominelt kr. 1,00 i Selskabet til en tegningspris på kr. 87,45 ("Tegningskursen").

6.2 Tegningskursen kan reguleres som an-ført i Aftalen.

The Warrant Holder is entitled to exercise all or part of his or her Warrants, however, the Warrant Holder cannot exercise less than 25 per cent of the total number of Warrants granted in accordance with this Agreement at a time.

4 Extraordinary Exercise of the Warrants

See exhibit 8.1.A (no changes).

5 Practicalities in connection with Exercise of the Warrants

See exhibit 8.1.C (no changes).

6 Subscription Price for Shares in connection with the Exercise of Warrants

Each Warrant entitles the Warrant Holder to subscribe for 1 share in the Company of a nominal value of DKK 1.00 at a subscription price of DKK 87.45 (the "Subscription Price").

The Subscription Price may be regulated as set out in this Agreement.



7 Regulering af vilkår for Warrants ved visse definerede ændringer i Selskabets kapitalforhold	7 Adjustment of the Conditions for Warrants in case of certain defined Changes in the Company's Capital Structure
7.1 Se bilag 8.1.A (ingen ændringer).	See exhibit 8.1.A (no changes).
8 Omsættelighed	8 Transferability
8.1 Se bilag 8.1.A (ingen ændringer).	See exhibit 8.1.A (no changes).
9 Vilkår for nye aktier udstedt ved udnyttelse af Warrants	9 Conditions for New Shares issued following Exercise of the Warrants
9.1 Se bilag 8.1.A (ingen ændringer).	See exhibit 8.1.A (no changes).
10 Kapitalforhøjelse ved udnyttelse af Warrants	10 Capital Increase in connection with the Exercise of the Warrants
10.1 Såfremt Warrantinnehaveren giver rettidig meddelelse om udnyttelse af Warrants, skal Selskabet gennemføre den dertil hørende kapitalforhøjelse.	In the event that the Warrant Holder gives notification on time of the exercise of the Warrants, the Company shall carry out the relating increase of capital.
10.2 Størstbeløbet af den kapital, der kan tegnes på grundlag af Warrants er nominelt kr. 389.762 (op til 389.762 aktier à kr. 1,00) og mindstebeløbet er kr. 1,00 (1 aktie à kr. 1,00) Størstbeløbet kan forøges eller reduceres i henhold til bestemmelserne om regulering i punkt 7. I henhold til punkt 1.2 udgør det konkrete antal tildelte warrants 386.012.	The maximum increase of capital that may be subscribed on basis of Warrants is nominally DKK 389,762 (up to 389,762 shares at DKK 1.00 each) and the minimum amount is DKK 1.00 (1 share at DKK 1.00) The maximum amount may be increased or reduced in accordance with the provisions on adjustment set forth in Clause 7. According to Clause 1.2 the final number of warrants granted is 386,012.



11 Omkostninger i forbindelse med udstedelse af aktier	11 Costs related to the Issue of Shares
11.1 Se bilag 8.1.A (ingen ændringer).	See exhibit 8.1.A (no changes)
12 Ophør af ansættelsesforholdet - Warrantinnehavere, der er medarbejdere	12 Cease of Employment Status - Warrant Holders who are Employees
12.1 Se bilag 8.1.A (ingen ændringer).	See exhibit 8.1.A (no changes).
13 Insiderhandel	13 Insider Trading
13.1 Se bilag 8.1.A (ingen ændringer).	See exhibit 8.1.A (no changes).
14 Skattemæssige forhold	14 Tax Implications
14.1 Warrants skal være underlagt bestemmelserne i ligningslovens § 28.	Warrants shall be subject to the provisions of Section 28 of the Danish Tax Assessment Act.
14.2 Samtlige skattemæssige forpligtelser og konsekvenser for Warrantinnehaverne som følge af Warrantaftalerne, de udstedte Warrants eller de erhvervede aktier gennem udnyttelse af disse Warrants er alene Warrantinnehavernes ansvar og er Selskabet uvedkommende.	All tax obligations and consequences to the Warrant Holder resulting from this Agreement, the Warrants issued or the shares acquired by the exercise of such Warrants, are the sole responsibility of the Warrant Holder and of no concern to the Company.
14.3 Warrantinnehaverne er kraftigt opfordret til at søge skattemæssig rådgivning i forbindelse med indgåelsen af Warrantaftalerne.	The Warrant Holder is strongly encouraged to seek tax advice in connection with entering into this Agreement.
15 Sprog	15 Language
15.1 Se bilag 8.1.A (ingen ændringer)	See exhibit 8.1.A (no changes).